ATE236881T1 - Durch strahlung aktivierte cytotoxin therapie - Google Patents

Durch strahlung aktivierte cytotoxin therapie

Info

Publication number
ATE236881T1
ATE236881T1 AT96927219T AT96927219T ATE236881T1 AT E236881 T1 ATE236881 T1 AT E236881T1 AT 96927219 T AT96927219 T AT 96927219T AT 96927219 T AT96927219 T AT 96927219T AT E236881 T1 ATE236881 T1 AT E236881T1
Authority
AT
Austria
Prior art keywords
tumour cells
radiation
racp
prodrug
effector
Prior art date
Application number
AT96927219T
Other languages
English (en)
Inventor
William Alexander Denny
Moana Tercel
William Robert Wilson
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ATE236881T1 publication Critical patent/ATE236881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
AT96927219T 1995-08-18 1996-08-19 Durch strahlung aktivierte cytotoxin therapie ATE236881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ27281595 1995-08-18
PCT/NZ1996/000085 WO1997007101A1 (en) 1995-08-18 1996-08-19 Radiation-activated cytotoxin therapy

Publications (1)

Publication Number Publication Date
ATE236881T1 true ATE236881T1 (de) 2003-04-15

Family

ID=19925392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927219T ATE236881T1 (de) 1995-08-18 1996-08-19 Durch strahlung aktivierte cytotoxin therapie

Country Status (9)

Country Link
US (1) US6071908A (de)
EP (2) EP0850224B1 (de)
JP (1) JP2000502988A (de)
AT (1) ATE236881T1 (de)
AU (1) AU722191B2 (de)
CA (1) CA2229460A1 (de)
DE (1) DE69627355T2 (de)
ES (1) ES2196165T3 (de)
WO (1) WO1997007101A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465882B1 (de) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
CN113101372B (zh) * 2019-12-24 2025-02-14 北京大学 具有辐射响应基团的缀合物及其用途
CN120899945A (zh) * 2025-10-11 2025-11-07 浙江大学 一种基于有机-无机动态组装的肿瘤靶向诊疗一体化系统及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296030A (en) * 1980-04-09 1981-10-20 American Cyanamid Company Metal chelates of 1,4-bis(substituted-amino-5,8-dihydroxy-anthraquinones
NZ201084A (en) * 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such

Also Published As

Publication number Publication date
EP1225169A1 (de) 2002-07-24
ES2196165T3 (es) 2003-12-16
EP0850224B1 (de) 2003-04-09
DE69627355D1 (de) 2003-05-15
AU722191B2 (en) 2000-07-27
US6071908A (en) 2000-06-06
AU6711196A (en) 1997-03-12
EP0850224A1 (de) 1998-07-01
WO1997007101A1 (en) 1997-02-27
DE69627355T2 (de) 2004-02-12
CA2229460A1 (en) 1997-02-27
JP2000502988A (ja) 2000-03-14

Similar Documents

Publication Publication Date Title
NZ292854A (en) Use of an photoactive compound to treat multiple sclerosis which is followed by light therapy
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
EP0802782A4 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
NZ333315A (en) Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions
CA2168575A1 (en) Use of photodynamic therapy to treat prostatic tissue
RU94045155A (ru) Способы ингибирования болезни альцгеймера
GR3034099T3 (en) Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
DE69231298D1 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
EP0746313A4 (de) Verfahren zur behandlung von kleinen mundgeschwüren
ATE173726T1 (de) 3-hydroxypyridin-4-on-derivate als chelatbildner
DE69627355D1 (de) Durch strahlung aktivierte cytotoxin therapie
GR3032041T3 (en) Idebenone compositions for treating Alzheimer&#39;s disease.
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NZ242748A (en) Compositions containing a pseudocatalase for treating depigmentation disorders
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
Chor et al. Successful treatment of oral lesions of chronic lichenoid graft‐vs.‐host disease by the addition of low‐level laser therapy to systemic immunosuppression
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
GB9216297D0 (en) Therapeutic agents
ATE435023T1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
SU782810A1 (ru) Способ лечени кератитов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties